At the end of this study, 74 patients had been diagnosed for a condyloma out of a total number of 3553 patients received during the study period, ie a prevalence of 2.1%. The relative prevalence was 28.2% to the 262 patients diagnosed for an STI of any category. The middle age of the patients was 35.1 ± 10.3 years and the median age was 33 years with extremes of 22 years and 68 years. The sex ratio was 9.6 (or 67 men for 7 women). There were 42 civil servants representing 57% of the patients followed 17 artisans and workers (23%), and 15 traders or ressellers (20%). Thirty-nine patients (52.7%) had higher education, 21 patients (28.4%) had secondary education and 14 patients (18.9%) had left primary school. Patients were from Cotonou (36% or 48.6%), Abomey-Calavi (22 or 29.7%), Porto-Novo (13% or 17.6%), Allada (2% or 2.7%) and Lokossa (1.4%).

The lesions were in the external genital organs (glans, penis, urethra, vulva) in 70% of the cases followed by inguinal folds and scrotum (8%) and anus and anal margin (3%). In 19% of the cases, the lesions had a multiple localization. According to the clinical form, 61 cases (or 82.4%) of acuminated condyloma (Figure 1), 8 cases (or 10.8%) of papular condylomas (Figure 2) and 5 cases (or 6.8%) of giant condylomas (Figure 3 and Figure 4).

A combination of two or three STIs was observed in 30 patients (40.5%). There were two cases (2.70%) of genital herpes, one case (1.35%) of syphilis, one case (1.35%) of chlamydia, two cases (2.70%) of scabiosis and 13 cases (17.56%) of genital candidiasis. HIV serology was positive in 12 patients or 16.2% of cases.

At the first consultation, 69 patients (93.2%) received treatment. Fifty-nine patients (79.7%) received electrocoagulation. In 33 patients (44.6%), electrocoagulation was associated with interferon alpha. Ten patients (13.5%) were treated with low-dose of interferon alpha and podophylotoxin.

The five patients (6.8%) who were not treated at the first consultation for lack of financial means were lost to follow-up. Of the 69 patients treated, 40 (or 58%) were lost to follow-up after the first consultation, 18 were cured (26.1%) after an average follow-up period of 02 years and 11 (or 15.9%) recidivated after an average of three months, requiring electrocoagulation with a favorable evolvement.

Human papillomavirus infections are the most common STIs in the world. Our study agrees in the same direction. Only 5% of the world population has clinical lesions. The latent form represents 25% of young people under 25 years old. The prevalence of papillomavirus infections is increasing in all countries [7] .

In our study, the overall prevalence of condylomas was 2.08%. It is 1% in Western countries. The majority of patients were men. This result agrees with that of Mahé and al [8] . Indeed, the latter also found that men represented the population mostly taken in charge by dermatologists. In addition, they noted that female dermatologists had a more readily mixed clintele, whereas male dermatologists saw almost exclusively men. In contrast, Faye and al. [9] in Mali rated 106 women for 43 men, a sex ratio of 0.40.

The middle age of the patients was 35 years, which is in agreement with the data of the literature. Lukasiewicz and al. [10] , that found an average age of 31 years.

The diagnosis of condylomas is mostly clinical [7] ; therefore no paraclinical examination is required most of the time except in rare cases where histopathological examination is indispensable.

The localizations and clinical forms of the lesions observed in our patients are in agreement with the literature which proves that the condylomas can be macular, papular or acuminate, even giant; They can sit on the vulva, the pubis, the glans, the balano-genital groove, the rod, the scrotum, the inguinal folds, inter-gluteal folds, the anal margin; as well as several seats can be found in the same patient [5] [7] . It is noted that the longer the consultation period, the more extensive or diffuse the lesions are.

Retroviral and syphilitic serology were negative in the majority of patients; which also explains the low number of giant condylomas observed in the latter on the one hand and the recidivism rate in agreement with the data from the literature. Because immunosuppressed and HIV-positive patients are known to have a high risk of HPV infection [11] [12] , with more exuberant and profuse forms of condyloma, and are also prone to therapeutic failures and recurrences.

There is no effective antiviral treatment for condylomas. The objective is the disappearance of visible lesions. The treatment is based on a multidisciplinary collaboration (dermatologists, gynecologists, urologists, proctologists). Patient information before treatment prevents confusion (HPV/cancer, viral infection/disease).

According to the recommendations of Bouscarat and al. [7] , published in the annals of dermatology and venereology of October 2016, there are three types of therapeutic methods: chemical treatments (self-applied cytotoxic: podophyllotoxin, 5 fluorouracil; or non self-applied: podophyllin, Trichloroacetic acid), immunomodulator treatment (Imiquimod), and destructive or ablative physical treatments (cryotherapy, laser, electrosurgery, or surgical excision).

But other therapeutic methods are also proposed in the literature such as: dynamic phototherapy combined with other destructive modalities that could increase the cure rate of genital warts. The quadrivalent vaccine against HPV 6, 11, 16, 18 has also been proposed to reduce the incidence of warts in the Western world [13] .

Hemper and al. treated a case of perineal giant condyloma by a heavy surgery with flaps of reconstruction and colostomy [14] .

Cidofovir intravenous (IV) is also an important therapeutic option in the treatment of severe or recurrent HPV infections, particularly in immunosuppressed patients [15] .

But unfortunately in Benin, our therapeutic arsenal is very limited. Our patients were treated mainly by electrocoagulation. Low-dose interferon alpha was used only as an adjuvant, and podophylotoxin alone was only a standby treatment in the latter.

Only 29 patients (39.2%) had been reviewed after treatment and 58% were lost to follow-up at the first control visit. This significant rate of loss of following-up could be justified either by a satisfactory evolution of the treatment with the absence of recurrence. Nevertheless, we recorded 15.9% of recidivism. This apparently low rate could be underestimated by the large number of people lost to follow-up. Only an active search for these people could edify us on their becoming and the real evolution of their disease. In the literature, all treatments have a failure rate of at least 30% and high recurrence rates at 3 months. [7] This rate of recurrence is also identical whatever the method used (about 30%), considering the possibility of asymptomatic viral infection [16] .